OpenNashEarnings

Medical Devices · NYSE: SYK

Stryker earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends December · next results expected around 28 Jan 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q3 2026

Stryker became exclusive U.S. sales agent for CMR Surgical's Versius robot, a first step into soft-tissue robotics, while a hip and knee slowdown and execution distractions held back orthopaedics.

Mako-related demand was strong, with Ortho Tech and Endoscopy leading growth. Hip and knee procedures slowed, driven by affordability concerns and more pre-authorization denials. Stryker also did not win share at its usual pace, with the cyber incident and an SAP rollout distracting its orthopaedics sales teams. Peripheral vascular improved as supply recovered, helped by a one-time payment from a China joint venture. Capital equipment demand stayed strong, and Stryker closed the ZuriMed acquisition for rotator cuff repair.

Read the Q3 2026 summary →

Quarters

KPI history

Revenue$6.5B+7.6% y/yQ3 2026
Q4 2024: $6.4BQ4 ’24$6.4BQ1 2025: $5.9BQ1 ’25$5.9BQ2 2025: $6.0BQ2 ’25$6.0BQ3 2025: $6.1BQ3 ’25$6.1BQ4 2025: $7.2BQ4 ’25$7.2BQ1 2026: $6.0BQ1 ’26$6.0BQ2 2026: $6.6BQ2 ’26$6.6BQ3 2026: $6.5BQ3 ’26$6.5B
Data
Q4 2024$6.4B
Q1 2025$5.9B
Q2 2025$6.0B
Q3 2025$6.1B
Q4 2025$7.2B
Q1 2026$6.0B
Q2 2026$6.6B
Q3 2026$6.5B
Diluted EPS (GAAP)$1.96−11.7% y/yQ3 2026
Q4 2024: $1.41Q4 ’24$1.41Q1 2025: $1.69Q1 ’25$1.69Q2 2025: $2.29Q2 ’25$2.29Q3 2025: $2.22Q3 ’25$2.22Q4 2025: $2.20Q4 ’25$2.20Q1 2026: $1.93Q1 ’26$1.93Q2 2026: $3.30Q2 ’26$3.30Q3 2026: $1.96Q3 ’26$1.96
Data
Q4 2024$1.41
Q1 2025$1.69
Q2 2025$2.29
Q3 2025$2.22
Q4 2025$2.20
Q1 2026$1.93
Q2 2026$3.30
Q3 2026$1.96

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin15.9%−2.8 pts y/yQ3 2026
Q4 2024: 9.0%Q4 ’249.0%Q1 2025: 14.3%Q1 ’2514.3%Q2 2025: 18.5%Q2 ’2518.5%Q3 2025: 18.7%Q3 ’2518.7%Q4 2025: 25.2%Q4 ’2525.2%Q1 2026: 15.5%Q1 ’2615.5%Q2 2026: 25.2%Q2 ’2625.2%Q3 2026: 15.9%Q3 ’2615.9%
Data
Q4 20249.0%
Q1 202514.3%
Q2 202518.5%
Q3 202518.7%
Q4 202525.2%
Q1 202615.5%
Q2 202625.2%
Q3 202615.9%
Free cash flow$1.2B−9.5% y/yQ3 2026
Q4 2024: $1.7BQ4 ’24$1.7BQ1 2025: $127.0MQ1 ’25$127.0MQ2 2025: $928.0MQ2 ’25$928.0MQ3 2025: $1.4BQ3 ’25$1.4BQ4 2025: $1.9BQ4 ’25$1.9BQ1 2026: $415.0MQ1 ’26$415.0MQ2 2026: $1.1BQ2 ’26$1.1BQ3 2026: $1.2BQ3 ’26$1.2B
Data
Q4 2024$1.7B
Q1 2025$127.0M
Q2 2025$928.0M
Q3 2025$1.4B
Q4 2025$1.9B
Q1 2026$415.0M
Q2 2026$1.1B
Q3 2026$1.2B

Operating cash flow minus capital expenditure, from cash flow statements.

Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Revenue$6.4B$5.9B$6.0B$6.1B$7.2B$6.0B$6.6B$6.5B
Gross margin64.9%63.8%63.8%63.6%64.5%63.3%68.3%65.2%
Operating income$581.0Md$837.0M$1.1B$1.1B$1.8Bd$936.0M$1.7B$1.0B
Operating margin9.0%14.3%18.5%18.7%25.2%15.5%25.2%15.9%
Net income$546.0M$654.0M$884.0M$859.0M$849.0M$745.0M$1.3B$753.0M
Diluted EPS$1.41$1.69$2.29$2.22$2.20$1.93$3.30$1.96
Operating cash flow$1.9Bd$250.0M$1.1Bd$1.5Bd$2.1Bd$581.0M$1.3Bd$1.5Bd
Capital expenditure$266.0Md$123.0M$183.0Md$187.0Md$268.0Md$166.0M$202.0Md$237.0Md
Free cash flow$1.7B$127.0M$928.0M$1.4B$1.9B$415.0M$1.1B$1.2B
R&D expense$358.0Md$405.0M$407.0M$410.0M$401.0Md$413.0M$434.0M$433.0M

From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.

10-K and 10-Q filings